Michael D Taylor

Operating Partner

Mission BioCapital

Present

Mission BioCapital brings together two U.S.-based early-stage life science venture funds: BioInnovation Capital and Mission Bay Capital. As Operating Partner, I work closely with some exceptionally talented young management teams for MBC's portfolio companies. Currently I am Executive Chairman for Mitokinin Therapeutics, Telo Therapeutics, Epiodyne, and ARase Therapeutics.

Director

Deciphera Pharmaceuticals

Senior Advisor

Deciphera Pharmaceuticals, Inc. · Waltham, Massachusetts

President & Ceo

Deciphera Pharmaceuticals, Inc. · Waltham, Massachusetts

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candida…

President & Ceo

Ensemble Therapeutics Corp.

CEO of groundbreaking Drug Discovery Company developing a novel class of therapeutics. Completed 7 Research Alliances with Major Pharma partners. Co-inventor of first-in-class small molecule inhibitors of IL-17, an important clinically-validated autoimmune modulator.

Director

Marina Biotech

Served as Independent Director of this public company, including Audit, Compensation and Nominating Committees.

Director

Cequent Pharmaceuticals

Served as Independent Director.

Senior Vice President

Pfizer

2000-2006 Global Head, project and portfolio management 2006-2007 Investor Development & Strategy

Drug Development Vice President

Warner Lambert

Led preclinical through late-stage development teams in oncology, cardiovascular, and neurology including Lipitor, Caduet, Neurontin, conivaptan, Onyx-015, suramin and SNX-111 during development, registration, and/or post-launch stages.

Drug Development Vp

Parke-Davis Pharmaceutical Research

Led preclinical through late-stage development teams in oncology, cardiovascular, and neurology including Lipitor, Caduet, Neurontin, conivaptan, Onyx-015, suramin and SNX-111 during development, registration, and/or post-launch stages.